TP53 and ovarian cancer: Interestingly, treatment of ovarian cancer patients by reintroduction of functional p53 into the ovarian cancer cells using an adenoviral vector, did not improve clinical response to treatment with carboplatin and paclitaxel, despite preclinical studies showing promise.